CHEST Clinical Trials Opportunities

Expose New Therapies. Improve Patient Lives.

Clinical Trials hero image

CHEST Clinical Trials Opportunities

Clinical trials power medical progress and allow principal investigators to test new ways to prevent, detect, and treat respiratory disease. There are numerous clinical trials underway at any given time. CHEST provides a service to help identify the clinical trials that may be of most interest to you.

How does it work?

By partnering with leading pharmaceutical and medical device companies, we help connect you with principal investigator opportunities that align with your interests, experience, and patient populations.

Principal investigator benefits:

  • Gain an advanced skill set in your area of specialty
  • Discover new treatment options that will advance patient care
  • Explore cutting-edge medical therapies to improve your practice

Ready to get started?

Fill out the form below and we’ll notify you when a clinical trial opportunity in your area of interest is underway. From there, you can decide whether or not participating in that trial would be a good fit.

Other Opportunities in Clinical Trials

Listed below are additional ongoing clinical trials in pulmonary, critical care, and sleep medicine being conducted by pharmaceutical and medical device companies.  A complete US Clinical Trial listing can be found at

For patients with IPF who may or may not already be taking either pirfenidone or nintedanib, Genentech is running a global multicenter phase 3 clinical trial to evaluate the safety and effectiveness of recombinant human pentraxin-2 (rhPTX-2; also known as PRM-151). This phase 3 trial is being initiated based upon the results from the phase 2 trial of rhPTX-2, which demonstrated statistically significant and clinically meaningful outcomes in patients with IPF (Raghu et al. JAMA. 2018;319(22):2299-2307).

A number of clinical trial sites are anticipated to be set up across the United States. For additional information, please contact Genentech at +1 (888) 662-6728 or visit

A study to assess the efficacy of a single oral dose of baloxavir marboxil vs placebo to reduce the direct transmission of influenza A or B in households is taking place at multiple sites around the United States and other countries. It is open to otherwise healthy participants between the ages of 5 and 64 with confirmed influenza infection who have had influenza symptoms for no more than 48 hours. Participants must also have at least two household members who are confirmed influenza-negative and are willing to participate.

Visit Centerstone for more information.

Do your patients with moderate to severe allergic asthma have difficulty exercising or sleeping? Genentech is doing an open label study investigating the impact of omalizumab on exercise capacity, physical activity, and sleep. If you treat patients over 18 with moderate to severe allergic asthma who would like to participate, or if you would like to learn more about the clinical study, contact Genentech at +1 (888) 662-6728 or visit

Are You an Industry Member?

Are you a pharmaceutical or medical device company looking for principal investigators? Discover all the ways in which CHEST can help you find the right clinicians for the right research study.



The American College of Chest Physicians (CHEST), in furtherance of its mission of advancing research, has established this page to provide a list of clinical trial-seeking individuals to serve as principal investigators or to otherwise participate. CHEST has neither conducted an independent investigation of the nature, quality, scientific merit, or subject matter of the clinical trials, nor has it established criteria or preconditions for those trials being listed on this page. CHEST, its officers, regents, members, and employees are not recommending or endorsing the listed trials or the companies sponsoring trials and specifically disclaims liability for damages of any kind arising out of a member, health care provider, or any other individual’s participation in a listed trial.